We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+3.02%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$751M
AUM Growth
-$32.5M
Cap. Flow
+$2.11M
Cap. Flow %
0.28%
Top 10 Hldgs %
35.59%
Holding
104
New
11
Increased
46
Reduced
31
Closed
15

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$22.1M
2
SYK icon
Stryker
SYK
+$18.4M
3
VRDN icon
Viridian Therapeutics
VRDN
+$14.4M
4
MCK icon
McKesson
MCK
+$12.9M
5
UNH icon
UnitedHealth
UNH
+$11.4M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$23.8M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$16.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$12.7M
4
LLY icon
Eli Lilly
LLY
+$10.1M
5
UTHR icon
United Therapeutics
UTHR
+$9.76M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$165B
$34.6M 4.61%
374,825
+245,800
+191% +$22.1M
VRNA
2
DELISTED
Verona Pharma
VRNA
$33.5M 4.46%
720,657
+94,205
+15% +$3.54M
PODD icon
3
Insulet
PODD
$9.79B
$32.8M 4.37%
125,761
-33,928
-21% -$8.54M
BSX icon
4
Boston Scientific
BSX
$71.5B
$30.1M 4.01%
337,354
-109,842
-25% -$9.67M
SYK icon
5
Stryker
SYK
$130B
$28M 3.73%
77,717
+49,717
+178% +$18.4M
COO icon
6
Cooper Companies
COO
$14.5B
$25.2M 3.36%
274,569
-18,024
-6% -$1.84M
LLY icon
7
Eli Lilly
LLY
$1.06T
$21.7M 2.9%
28,163
-12,221
-30% -$10.1M
VRDN icon
8
Viridian Therapeutics
VRDN
$2.67B
$20.8M 2.78%
1,087,634
+662,634
+156% +$14.4M
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$20.3M 2.7%
243,123
+1,548
+0.6% +$127K
MNKD icon
10
MannKind Corp
MNKD
$1.32B
$20.1M 2.68%
3,126,727
-177,358
-5% -$1.19M
ABT icon
11
Abbott
ABT
$187B
$20M 2.67%
176,994
+53,393
+43% +$6.17M
TVTX icon
12
Travere Therapeutics
TVTX
$5.78B
$19.5M 2.59%
1,117,792
+31,725
+3% +$561K
RCUS icon
13
Arcus Biosciences
RCUS
$3.64B
$19M 2.53%
1,273,789
+248,035
+24% +$4.05M
BDX icon
14
Becton Dickinson
BDX
$48.2B
$16M 2.13%
70,404
+10,393
+17% +$2.4M
NBIX icon
15
Neurocrine Biosciences
NBIX
$16.6B
$15.8M 2.1%
115,727
-14,113
-11% -$1.75M
KNSA icon
16
Kiniksa Pharmaceuticals
KNSA
$5.93B
$15.1M 2.02%
765,453
+10,209
+1% +$233K
DGX icon
17
Quest Diagnostics
DGX
$26.3B
$13.6M 1.82%
90,352
+35,352
+64% +$5.5M
THC icon
18
Tenet Healthcare
THC
$21.1B
$13.5M 1.8%
106,987
+13,234
+14% +$1.97M
UTHR icon
19
United Therapeutics
UTHR
$23.1B
$13.2M 1.76%
37,472
-26,559
-41% -$9.76M
MCK icon
20
McKesson
MCK
$101B
$13.1M 1.75%
+23,000
New +$12.9M
DAWN
21
DELISTED
Day One Biopharmaceuticals
DAWN
$12.7M 1.69%
1,000,474
+76,334
+8% +$1.06M
QGEN icon
22
Qiagen
QGEN
$8.72B
$12.3M 1.64%
269,570
+64,656
+32% +$2.9M
CVRX icon
23
CVRx
CVRX
$63.4M
$11.7M 1.55%
921,174
+238,277
+35% +$2.94M
SDGR icon
24
Schrodinger
SDGR
$1.36B
$10.9M 1.45%
563,091
+3,986
+0.7% +$77.4K
EW icon
25
Edwards Lifesciences
EW
$51.7B
$10.8M 1.43%
+145,214
New +$10.2M
1
2 3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Parkman Healthcare Partners held 104 positions worth $751M, down 4.2% from $783M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Parkman Healthcare Partners's Q4 2024 filing shows 11 new, 46 increased, 31 reduced and 15 closed positions. Its largest new stake was McKesson: 23,000 shares worth $13.1M. The largest sale was Teleflex, an estimated $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Parkman Healthcare Partners's largest Q4 2024 buy was McKesson: 23,000 shares worth $13.1M.
  • Parkman Healthcare Partners added most to Gilead Sciences in Q4 2024, an estimated $22.1M increase.
  • Parkman Healthcare Partners's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $10.1M.
  • Parkman Healthcare Partners fully exited Teleflex in Q4 2024, selling an estimated $23.8M.
  • Parkman Healthcare Partners's ten largest holdings make up 36% of its $751M portfolio in Q4 2024.
  • Parkman Healthcare Partners opened 11 new positions and closed 15 in Q4 2024.
  • Parkman Healthcare Partners's portfolio value fell 4.2% quarter-over-quarter to $751M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2024, filed 14 Feb 2025.